Literature DB >> 11240083

Neuropeptide Y in trigeminal ganglion following chronic constriction injury of the rat infraorbital nerve: is there correlation to somatosensory parameters?

R Benoliel1, E Eliav, M J Iadarola.   

Abstract

The aim of this study was to investigate neuropeptide Y (NPY) levels in trigeminal ganglia following infraorbital nerve injury. Two experimental procedures were performed in three groups of rats: a unilateral chronic constriction injury (CCI) to the infraorbital nerve (n=13), nerve manipulation without CCI (n=13) and unoperated controls (n=8). All rats underwent baseline and regular assessment of mechanical withdrawal threshold (Von Frey) and reaction to pin prick as well as free behavior evaluations. CCI to the infraorbital nerve induced significant hyperalgesia and allodynia within 9-12 days. At 6 days seven rats were euthanized and trigeminal ganglia harvested for immunocytochemical (ICC) studies. The study was ended at 14 days when all rats were euthanized and their ganglia harvested for ICC and radioimmunoassay (RIA) studies. An increase in NPY levels was seen in the ipsilateral ganglia of manipulated and CCI rats at 6 days, when rats displayed no pain-related behavior. At 14 days, ICC and RIA both detected significant increases in NPY levels in the ipsilateral ganglia of CCI and manipulated rats but not in unoperated controls. The possible roles of NPY in pain modulation and nerve injury are discussed in light of these findings.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11240083     DOI: 10.1016/s0304-3959(00)00417-6

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  8 in total

1.  The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain.

Authors:  Valérie Kayser; Bertrand Aubel; Michel Hamon; Sylvie Bourgoin
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Neuropeptide Y modulates effects of bradykinin and prostaglandin E2 on trigeminal nociceptors via activation of the Y1 and Y2 receptors.

Authors:  J L Gibbs; A Diogenes; K M Hargreaves
Journal:  Br J Pharmacol       Date:  2006-12-04       Impact factor: 8.739

3.  Sigma-1 receptor modulates neuroinflammation associated with mechanical hypersensitivity and opioid tolerance in a mouse model of osteoarthritis pain.

Authors:  Mireia Carcolé; Sami Kummer; Leonor Gonçalves; Daniel Zamanillo; Manuel Merlos; Anthony H Dickenson; Begoña Fernández-Pastor; David Cabañero; Rafael Maldonado
Journal:  Br J Pharmacol       Date:  2019-09-12       Impact factor: 8.739

Review 4.  Perspectives on next steps in classification of oro-facial pain - Part 3: biomarkers of chronic oro-facial pain - from research to clinic.

Authors:  W Ceusters; C Nasri-Heir; D Alnaas; B E Cairns; A Michelotti; R Ohrbach
Journal:  J Oral Rehabil       Date:  2015-07-22       Impact factor: 3.837

5.  Chemogenetic inhibition of trigeminal ganglion neurons attenuates behavioural and neural pain responses in a model of trigeminal neuropathic pain.

Authors:  Olga A Korczeniewska; Morgan H James; Tali Eliav; Giannina Katzmann Rider; Jacqueline B Mehr; Hafsa Affendi; Gary Aston-Jones; Rafael Benoliel
Journal:  Eur J Pain       Date:  2021-12-06       Impact factor: 3.931

6.  The Persistent Pain Transcriptome: Identification of Cells and Molecules Activated by Hyperalgesia.

Authors:  Matthew R Sapio; Jenny J Kim; Amelia J Loydpierson; Dragan Maric; Taichi Goto; Fernando A Vazquez; Mary K Dougherty; Radhika Narasimhan; Wallis T Muhly; Michael J Iadarola; Andrew J Mannes
Journal:  J Pain       Date:  2021-04-20       Impact factor: 5.383

7.  Novel expression pattern of neuropeptide Y immunoreactivity in the peripheral nervous system in a rat model of neuropathic pain.

Authors:  Claire Magnussen; Shih-Ping Hung; Alfredo Ribeiro-da-Silva
Journal:  Mol Pain       Date:  2015-05-27       Impact factor: 3.395

8.  Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes.

Authors:  Noo Ree Cho; Yeuni Yu; Chang-Kyu Oh; Dai Sik Ko; Kyungjae Myung; Yoonsung Lee; Hee Sam Na; Yun Hak Kim
Journal:  Ther Adv Chronic Dis       Date:  2021-09-08       Impact factor: 5.091

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.